source
- Arbitration panel rules Prime Medicine did not breach Beam deal over AATD therapyAn arbitration panel has ruled that Prime Medicine did not violate its 2019 collaboration agreement with Beam Therapeutics by advancing a treatment for alpha‑1 antitrypsin deficiency (AATD). The de…
- Sino Biopharm signs separate respiratory partnership deals with AstraZeneca and GSKSino Biopharm announced it has entered into two distinct agreements with UK-based pharmaceutical companies focused on respiratory medicines. One agreement involves licensing its investigational PD…